• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Severe Asthma Research Quiz: 8 Questions on Notable New Findings

Slideshow

New study findings on asthma exacerbation risk prediction, rapid steroid reduction, and patient perception of disease lead this quick quiz.

A recent review of research on severe asthma diagnosis and management found a wide range of interesting, even provocative, results.

The 8 questions that follow reflect that range of findings including new GINA treatment recommendations, a rapid corticosteroid reduction plan, patient perception of disease severity, and refined prediction of exacerbation risk.

Good luck!

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets Primary End Point / image credit BI logo: ©Michael_Vi/stock.adobe.com

IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets Primary End Point

Hayden E. Klein
September 19th 2024
Article

The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD / Image credit: ©Oleksandr/AdobeStock

Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD

Brooke McCormick
September 6th 2024
Article

In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Long Colds: Managing patient expectations about duration of the common cold image credit: epocrates, Anne Meneghetti, MD

Long Colds: How to Manage Patient Expectation About Duration of the Common Cold

Anne Meneghetti, MD
July 31st 2024
Article

Patients largely underestimate how long a cold should last and the lingering symptoms too often prompt a request for antibiotics. Primary care, please resist!

ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses / image credit body in pain: ©Lila Patel via AI/stock.adobe.com

ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses

Grace Halsey
July 24th 2024
Article

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

© 2024 MJH Life Sciences

All rights reserved.